Current status of recurrent glioblastoma therapies

Ali Syed Arbab

doi:10.1016/B978-0-12-822527-1.00015-0

Current status of recurrent glioblastoma therapies

Research output: Chapter in Book/Report/Conference proceeding › Chapter

Abstract

Almost 100% glioblastoma (GBM) recurs following extensive therapies. Current strategies of treatment of recurrent GBM varies from center to center and it depends on the site, size, and vascularity of the recurrent tumors. In this chapter, current views of managing recurrent GBM is discussed and also possible alternative intervention is pointed out.

Original language	English (US)
Title of host publication	New Targeting in the Reversal of Resistant Glioblastomas
Publisher	Elsevier
Pages	1-7
Number of pages	7
ISBN (Electronic)	9780128225271
ISBN (Print)	9780128232767
DOIs	https://doi.org/10.1016/B978-0-12-822527-1.00015-0
State	Published - Jan 1 2021
Externally published	Yes

Keywords

Avastin
Current therapies
Glioblastoma (GBM)
Immunotherapies
Radiation
Temozolomide

ASJC Scopus subject areas

General Agricultural and Biological Sciences
General Biochemistry, Genetics and Molecular Biology

Access to Document

10.1016/B978-0-12-822527-1.00015-0

Cite this

@inbook{16ae46d430444c20bfbe5d791d863deb,

title = "Current status of recurrent glioblastoma therapies",

abstract = "Almost 100% glioblastoma (GBM) recurs following extensive therapies. Current strategies of treatment of recurrent GBM varies from center to center and it depends on the site, size, and vascularity of the recurrent tumors. In this chapter, current views of managing recurrent GBM is discussed and also possible alternative intervention is pointed out.",

keywords = "Avastin, Current therapies, Glioblastoma (GBM), Immunotherapies, Radiation, Temozolomide",

author = "Arbab, {Ali Syed}",

year = "2021",

month = jan,

day = "1",

doi = "10.1016/B978-0-12-822527-1.00015-0",

language = "English (US)",

isbn = "9780128232767",

pages = "1--7",

booktitle = "New Targeting in the Reversal of Resistant Glioblastomas",

publisher = "Elsevier",

address = "Netherlands",

}

TY - CHAP

T1 - Current status of recurrent glioblastoma therapies

AU - Arbab, Ali Syed

PY - 2021/1/1

Y1 - 2021/1/1

N2 - Almost 100% glioblastoma (GBM) recurs following extensive therapies. Current strategies of treatment of recurrent GBM varies from center to center and it depends on the site, size, and vascularity of the recurrent tumors. In this chapter, current views of managing recurrent GBM is discussed and also possible alternative intervention is pointed out.

AB - Almost 100% glioblastoma (GBM) recurs following extensive therapies. Current strategies of treatment of recurrent GBM varies from center to center and it depends on the site, size, and vascularity of the recurrent tumors. In this chapter, current views of managing recurrent GBM is discussed and also possible alternative intervention is pointed out.

KW - Avastin

KW - Current therapies

KW - Glioblastoma (GBM)

KW - Immunotherapies

KW - Radiation

KW - Temozolomide

UR - http://www.scopus.com/inward/record.url?scp=85142073535&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85142073535&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-822527-1.00015-0

DO - 10.1016/B978-0-12-822527-1.00015-0

M3 - Chapter

AN - SCOPUS:85142073535

SN - 9780128232767

SP - 1

EP - 7

BT - New Targeting in the Reversal of Resistant Glioblastomas

PB - Elsevier

ER -

Current status of recurrent glioblastoma therapies

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this